FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588570873> ?p ?o ?g. }

• W2588570873 endingPage "90" @default.
• W2588570873 startingPage "82" @default.
• W2588570873 abstract "To assess efficacy (event-free survival, EFS) and safety in patients followed up for 3 years in the PrefHer study (NCT01401166).Post surgery and post chemotherapy in the (neo)adjuvant setting, patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer were randomised to receive four cycles of the subcutaneous form of trastuzumab (Herceptin® SC [H SC] via single-use injection device [Cohort 1] or delivery via a hand-held syringe from an SC Vial [Cohort 2]; 600 mg fixed dose) followed by four of the intravenous form of trastuzumab (Herceptin® [H IV]; 8 mg/kg loading, 6 mg/kg maintenance doses) in the adjuvant setting or vice versa every 3 weeks. Patients could have received H before randomisation. H was then continued to complete a total of 18 cycles, including any cycles received before randomisation.A total of 488 patients were randomised across both cohorts. After median follow-up of 36.1 months, 3-year EFS across both groups in the evaluable intention-to-treat population (467 patients) was 90.6% overall, 89.9% in Cohort 1, and 91.1% in Cohort 2. No new safety signals were identified during long-term follow-up, with only one cardiac serious adverse event in the safety population (483 patients).Three-year EFS data following H SC and H IV treatment are consistent with those reported by previous trials for H in the adjuvant setting. The overall safety profile during adjuvant treatment was as expected." @default.
• W2588570873 created "2017-02-24" @default.
• W2588570873 creator A5008994423 @default.
• W2588570873 creator A5044903892 @default.
• W2588570873 creator A5046221783 @default.
• W2588570873 creator A5052765312 @default.
• W2588570873 creator A5070594128 @default.
• W2588570873 creator A5071971525 @default.
• W2588570873 creator A5072114014 @default.
• W2588570873 creator A5079115955 @default.
• W2588570873 creator A5086259587 @default.
• W2588570873 creator A5088637879 @default.
• W2588570873 date "2017-11-01" @default.
• W2588570873 modified "2023-09-26" @default.
• W2588570873 title "Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study" @default.
• W2588570873 cites W1549851394 @default.
• W2588570873 cites W1926958054 @default.
• W2588570873 cites W2024903800 @default.
• W2588570873 cites W2051855661 @default.
• W2588570873 cites W2057615228 @default.
• W2588570873 cites W2075894019 @default.
• W2588570873 cites W2090295140 @default.
• W2588570873 cites W2091276904 @default.
• W2588570873 cites W2098775844 @default.
• W2588570873 cites W2099067294 @default.
• W2588570873 cites W2101253730 @default.
• W2588570873 cites W2107103026 @default.
• W2588570873 cites W2130034035 @default.
• W2588570873 cites W2136166698 @default.
• W2588570873 cites W2137228442 @default.
• W2588570873 cites W2143967622 @default.
• W2588570873 cites W2146384083 @default.
• W2588570873 cites W2152647863 @default.
• W2588570873 cites W2164052013 @default.
• W2588570873 cites W2166199281 @default.
• W2588570873 cites W2169281409 @default.
• W2588570873 cites W2315066014 @default.
• W2588570873 cites W2320478156 @default.
• W2588570873 cites W2330930594 @default.
• W2588570873 cites W2331894260 @default.
• W2588570873 cites W2379981061 @default.
• W2588570873 cites W2404204869 @default.
• W2588570873 cites W2475799443 @default.
• W2588570873 cites W2494190003 @default.
• W2588570873 cites W2586849549 @default.
• W2588570873 cites W2592555179 @default.
• W2588570873 cites W2592999238 @default.
• W2588570873 cites W2617889858 @default.
• W2588570873 cites W2624590002 @default.
• W2588570873 cites W2688564736 @default.
• W2588570873 cites W4243091585 @default.
• W2588570873 doi "https://doi.org/10.1016/j.ejca.2017.08.019" @default.
• W2588570873 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28963915" @default.
• W2588570873 hasPublicationYear "2017" @default.
• W2588570873 type Work @default.
• W2588570873 sameAs 2588570873 @default.
• W2588570873 citedByCount "37" @default.
• W2588570873 countsByYear W25885708732018 @default.
• W2588570873 countsByYear W25885708732019 @default.
• W2588570873 countsByYear W25885708732020 @default.
• W2588570873 countsByYear W25885708732021 @default.
• W2588570873 countsByYear W25885708732022 @default.
• W2588570873 countsByYear W25885708732023 @default.
• W2588570873 crossrefType "journal-article" @default.
• W2588570873 hasAuthorship W2588570873A5008994423 @default.
• W2588570873 hasAuthorship W2588570873A5044903892 @default.
• W2588570873 hasAuthorship W2588570873A5046221783 @default.
• W2588570873 hasAuthorship W2588570873A5052765312 @default.
• W2588570873 hasAuthorship W2588570873A5070594128 @default.
• W2588570873 hasAuthorship W2588570873A5071971525 @default.
• W2588570873 hasAuthorship W2588570873A5072114014 @default.
• W2588570873 hasAuthorship W2588570873A5079115955 @default.
• W2588570873 hasAuthorship W2588570873A5086259587 @default.
• W2588570873 hasAuthorship W2588570873A5088637879 @default.
• W2588570873 hasBestOaLocation W25885708732 @default.
• W2588570873 hasConcept C121608353 @default.
• W2588570873 hasConcept C126322002 @default.
• W2588570873 hasConcept C141071460 @default.
• W2588570873 hasConcept C143998085 @default.
• W2588570873 hasConcept C168563851 @default.
• W2588570873 hasConcept C197934379 @default.
• W2588570873 hasConcept C201903717 @default.
• W2588570873 hasConcept C2777863537 @default.
• W2588570873 hasConcept C2779786085 @default.
• W2588570873 hasConcept C2908647359 @default.
• W2588570873 hasConcept C530470458 @default.
• W2588570873 hasConcept C71924100 @default.
• W2588570873 hasConcept C72563966 @default.
• W2588570873 hasConcept C99454951 @default.
• W2588570873 hasConceptScore W2588570873C121608353 @default.
• W2588570873 hasConceptScore W2588570873C126322002 @default.
• W2588570873 hasConceptScore W2588570873C141071460 @default.
• W2588570873 hasConceptScore W2588570873C143998085 @default.
• W2588570873 hasConceptScore W2588570873C168563851 @default.
• W2588570873 hasConceptScore W2588570873C197934379 @default.
• W2588570873 hasConceptScore W2588570873C201903717 @default.
• W2588570873 hasConceptScore W2588570873C2777863537 @default.
• W2588570873 hasConceptScore W2588570873C2779786085 @default.

• next